Ads
related to: Stage 4 Carcinoma Cancer and Cancer Patients- FAQs
Find FAQs For This Treatment
Option On The Official Patient Site
- How This Treatment Works
Learn More About How This
FDA-Approved Treatment Works.
- Clinical Trial Info
Review Clinical Trial Results For
This FDA-Approved Treatment Option.
- Dosing Information
Get Dosing And Treatment
Schedule Information.
- FAQs
Search results
Blood-Based Test for CRC Screening Hits Sensitivity, Specificity Endpoints
MedPage Today· 5 days agoA blood-based test for the early detection of colorectal cancer (CRC) met its prespecified...
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at...
NBC 10 - FOX 14 Monroe· 5 days agoOn May 10, 2024, Cure Genetics announced the safety and efficacy data of their CAR-NKT product, CGC729, for patients with relapsed and refractory metastatic renal cell < ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoHOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoPreliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 days ago- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 5 days agoCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral ...
Purple Biotech (NASDAQ:PPBT) Receives Buy Rating from HC Wainwright
ETF DAILY NEWS· 5 days agoPurple Biotech (NASDAQ:PPBT – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoMultiple refractory PD1 failure patients experienced prolonged progression free survival (10 months ongoing); confirmed responses observed in patients receiving ...
Bristol Myers (BMY) Updates Action Date for Subcutaneous Opdivo
Zacks via Yahoo Finance· 6 days agoIn the past 30 days, the Zacks Consensus Estimate for Ligand’s 2024 and 2025 earnings per share has...
Jump Financial LLC Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO)
ETF DAILY NEWS· 3 days agoJump Financial LLC purchased a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) during the fourth quarter, according to the company in its most recent disclosure ...